Children's Cancer Center, National Center for Child Health and Development, Setagaya, Tokyo, Japan.
Pediatr Blood Cancer. 2015 Mar;62(3):536-8. doi: 10.1002/pbc.25241. Epub 2014 Oct 12.
There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristine and propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1 mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimus should be further studied as an alternative agent to sirolimus in the management of KHE.
目前对于对泼尼松和长春新碱耐药的卡波西样血管内皮瘤（KHE）的二线治疗还没有共识。我们描述了一例 8 岁男性右股骨 KHE，对泼尼松、长春新碱和普萘洛尔耐药。依维莫司（mTOR 抑制剂）的剂量为 0.1mg/kg/天，成功地减小了肿瘤的大小并控制了症状。依维莫司应该进一步研究作为西罗莫司在 KHE 治疗中的替代药物。
